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Efficacy and Safety of Intravenous and Oral Nadolol for
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Johnson City, Tennessee
The efficacy and safety of oral nadolol in supraventricular tachy-
cardia were evaluated prospectively in 27 children (median age 5.5
years). Fifteen patients had an unsuccessful trial of digoxin
therapy. Intravenous nadolol was given to seven patients during
electrophysiologic study; five of these had an excellent response
and two had a partial response (25% decrease in tachycardia
rate). Six of these patients had a similar response to oral nadolol.
Twelve patients received both propranolol and nadolol. Among six
patients, intravenous propranolol was successful in four and
unsuccessful in two; all six had a similar response to oral nadolol.
With oral propranolol, tachycardia was well controlled in four
patients and persistent in two; five of five patients had a similar
response to oral nadolol.
Twenty-six patients were treated with oral nadolol; the ar-
Propranolol, a beta-adrenoceptor blocking agent, and dig-
oxin are used frequently as first-line drugs for supraventric-
ular tachycardia in children (1,2). During the last decade,
several new beta-adrenoceptor blocking agents have been
approved by the U.S. Food and Drug Administration. Al-
though these agents have many similar pharmacologic ef-
fects, they differ vastly in clinically important pharmacoki-
netic properties. One of these newer agents, nadolol
(Corgard) is a nonselective beta-adrenoceptor blocking
agent. It has been used in adults for the treatment of
supraventricular and ventricular arrhythmias (3-8), hyper-
tension and angina pectoris (9). Unlike propranolol, it has a
prolonged elimination half-life of 14 to 24 h, the longest of all
beta-adrenoceptor blocking agents (10,11). Its once a day
regimen with lack of significant side effects in adults (3-8)
makes it an attractive drug for use in children. However, its
use in children has not been reported previously.
The purpose of this study was to prospectively investi-
gate 1) the efficacy and safety of intravenous and oral nadolol
in children with recurrent symptomatic supraventricular
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rhythmia was well controlled in 23, 2 had recurrent tachycardia
and 1patient had tachycardia at a 25% slower rate. The effective
dose of nadolol ranged between 0.5 and 2.5 mg/kg body weight
once daily (median dose 1 mg/kg per day). During follow-up (3 to
36 months), compliance and tolerance were excellent; excluding 2
patients with reactive airway disease who developed wheezing,
only 3 (12%) of 24 had side effects necessitating a change in drug
therapy.
Once a day nadolol is a safe and effective agent in the
management of supraventricular tachycardia in children. Its
long-term efficacy can be predicted by the short-term response to
intravenous nadolol or propranolol during programmed electro-
physiologic study.
(J Am Coll CardioI1992;19:630-5)
tachycardia; 2) the ability of the response to intravenous or
oral propranolol to predict the efficacy of oral nadolol in
children with supraventricular tachycardia; 3) the effective-
ness of a once a day dosing interval; and 4) the effective
dosage range of nadolol.
Methods
Study patients. This prospective study included 27 chil-
dren :;;18 years of age with symptomatic supraventricular
tachycardia documented by a surface electrocardiogram
(ECG) or ambulatory ECG recording, or both. Children with
heart failure, sick sinus syndrome, atrial flutter or atrial
fibrillation were excluded. All children were seen in the
pediatric cardiac clinic by a cardiologist, either at St. Chris-
topher's Hospital for Children, Philadelphia or James H.
Quillen College of Medicine, Johnson City, Tennessee,
between July 1985 and June 1991.
Patients selected for the intravenous nadolol protocol
were required 1) to have supraventricular tachycardia that
was refractory to digoxin therapy despite a documented
therapeutic serum digoxin level; 2) to be undergoing clini-
cally indicated electrophysiologic study; and 3) to have given
prior written informed consent. Entry criteria for the oral
nadolol protocol included any of the following: 1) complete
or partial success (>25% decrease in tachycardia rate) of
intravenous nadolol during electrophysiologic study; 2) un-
successful treatment with digoxin despite a documented
therapeutic digoxin level; 3) success of intravenous or oral
0735-1097/92/$5.00
JACC Vol. 19, No.3
March I, 1992:630-5
MEHTA AND CHIDAMBARAM
NADOLOL IN PEDIATRIC ARRHYTHMIAS
631
propranolol, or both, with or without digoxin as assessed by
history or ambulatory ECG recording; 4) questionable com-
pliance with an oral propranolol regimen; and 5) the pres-
ence of a narrow QRS tachycardia on the ECG with or
without a documented accessory bypass tract. The intrave-
nous nadolol protocol was approved by the Institutional
Review Board of St. Christopher's Hospital for Children and
was used only at that center.
Study method. All children had a complete physical
examination, a 12-lead surface ECG, a complete echocardio-
gram and an ambulatory (Holter) ECG recording.
Intravenous nadolol protocol. All antiarrhythmic drugs
were discontinued 72 h before electrophysiologic study. The
study was performed with the patient in a postabsorptive
state under sedation with meperidine hydrochloride (2 mg/kg
body weight to a maximum of 50 mg intramuscularly) and
promethazine (0.5 mg/kg to a maximum of 12.5 mg intramus-
cularly). The electrophysiologic protocol included atrial ex-
trastimuli on sinus or paced beats, or both, rapid atrial
pacing for 30 s, ventricular extrastimuli on sinus or paced
beats, or both, and burst ventricular pacing for eight beats.
The extrastimuli were delivered at approximately twice
diastolic threshold by means of a programmed digital stim-
ulator. The extrastimuli were delivered at decreasing inter-
vals, starting at approximately 80% of the sinus or paced
cycle length. None of the patients received isoproterenol
infusion in this study.
After the mechanism of supraventricular tachycardia was
defined by the electrophysiologic protocol just described, a
single dose of intravenous nadolol, 0.05 mg/kg to a maximum
of 5 mg, was given over 2 min. Repeat electrophysiologic
studies were performed at intervals of 15 and 30 min. The
patient's blood pressure and ECG were continuously moni-
tored. If tachycardia was inducible, a second identical dose
of nadolol was given and the study was repeated at intervals
of 15 and 30 min. If tachycardia was not induced, nadolol
was considered successful and these patients entered the
oral nadolol protocol.
Propranolol protocol. The intravenous dose of proprano-
lol was 0.1 to 0.2 mg/kg to a maximum of 10 mg. The starting
oral propranolol dose was 2mg/kg per day, given in three or
four doses, and was gradually increased until there was no
clinical tachycardia, significant bradycardia (20% decrease
in heart rate) or any significant side effects. Propranolol was
considered successful if there was no inducible or clinical
tachycardia during follow-up. Subsequently, these children
were treated with nadolol according to the protocol.
Oral nadolol protocol. Children from the intravenous
nadolol or the propranolol protocol and children who had not
responded to digoxin or had not received any previous drug
therapy were included in the oral nadolol protocol. The
starting oral nadolol dose ranged from 0.5 to 1.5 mg/kg once
daily. Each child was followed up with telemetry monitoring
in the hospital or in outpatient examinations to detect
adverse drug effects, clinical tachycardia or ECG changes. If
tachycardia or adverse effects were not observed, the same
dose was continued. If any episode of tachycardia recurred
after the 4th day of therapy without side effects, the dose
was increased gradually to a maximum of 2.5 mg/kg per day.
If a child had recurrent tachycardia while receiving a maxi-
mal dose of nadolol or if side effects occurred, nadolol
therapy was discontinued.
Follow-up. Efficacy and side effects were assessed by
history, a complete physical examination and a 12-lead ECG
at least every month for 2 months and every 6 months
thereafter as needed. An ambulatory (Holter) ECG was
performed routinely in all patients <10 years old. Addition-
ally, an ambulatory ECG was performed in any child who
had symptoms or bradycardia.
Results
Clinical data. Twenty-seven patients (19 male and 8
female) were treated with nadolol under the protocol. The
age at the onset of supraventricular tachycardia ranged from
3 months to 15 years (median 6 years). All but one patient
received oral nadolol therapy. Patients were classified into
two groups: 1) Group I comprised 14 children who received
intravenous or oral propranolol or nadolol, or both (Table 1);
2) Group II comprised 13 children who received only oral
nadolol therapy (Table 2). Tables 1 and 2 summarize the
clinical characteristics of the patients in each group. Two
patients (Table 1, Patients 4 and 14) had congenital heart
disease. Only one patient (Group I, Patient 1) had echocar-
diographic evidence of ventricular dysfunction.
The mechanisms ofsupraventricular tachycardia were as
follows: an accessory bypass tract in 7patients; atrioventric-
ular (AV) node reentry in 4; automatic ectopic atrial tachy-
cardia in 1patient; automatic ectopic junctional tachycardia
in 2 patients; intraatrial reentry in 1 patient; sinus node
reentry in 2 patients and narrow QRS reentrant supraven-
tricular tachycardia in 10. Fifteen children had unsuccessful
digoxin therapy.
Response to intravenous and oral nadolol (Table 1). After
intravenous nadolol, two patients (Group I, Patients 8 and
10) with AV node reentrant tachycardia had no inducible
tachycardia; both were free of tachycardia on oral nadolol
therapy during follow-up. One patient (Group I, Patient 3)
with ectopic atrial tachycardia had conversion to sinus
rhythm with intravenous nadolol therapy and good control of
the arrhythmia with oral nadolol therapy. One patient
(Group I, Patient 6) with AV reciprocating tachycardia had
nonsustained inducible tachycardia « lO-s duration) after a
second dose of intravenous nadolol, but oral nadolol pro-
vided excellent clinical control of the tachycardia. Another
patient (Group I, Patient 7) showed similar responses, hav-
ing nonsustained inducible tachycardia 30 min after a single
dose of intravenous nadolol but no inducible tachycardia
45 min later; he was free of tachycardia with oral nadolol
therapy during follow-up. Two other patients, one with AV
node tachycardia and one with AV reciprocating tachycar-
dia, had sustained inducible tachycardia after a single intra-
632 MEHTA AND CHIDAMBARAM JACC Vol. 19, No.3
NADOLOL IN PEDIATRIC ARRHYTHMIAS March 1, 1992:630-5
Table 1. Group I: Summary of Data on 14 Children Who Received Intravenous or Oral Nadolol or Propranolol, or Both
Age at Age at Nadolol
Drug Response
Dose of Oral Duration of
PI SVT Onset Therapy Mechanism of SVT Propranolol Nadolol Nadolol Follow-Up;
No. Gender (yr) (yr) by EPS Digoxin IV/Oral IV/Oral (mglkg per day) Comments
1 F 1.5 3 Atrial reentry U U U U 2 6mo
2 F 13 15 AVNR U S S 1.75 1 yr
3 M 3 mo 3 mo Ectopic atrial U S S S S 1.5 3 mo; abdominal
colic
4 M 3.5 3.5 AVRT U U P 6 mo; 25%
decrease in SVT
rate; AV canal
repair
5 F 8 9.5 AVNR U U P P 1.5 1yr; 25% decrease
inSVT
6 M 1 1 AVRT U S S S 1.5 1yr
7 M 2 2.5 AVRT U S S 2.5 1.5 yr
8 M 2.5 3 AVNR U S S 2 I yr
9 M 15 15 AVRT S S 0.75 6mo
10 F 8 10 AVNR U S S S 0.7 6 mo; headache;
fatigue
11 M 15 15 SN reentry S S 1 6mo
12 F 5 6.5 AVRT U U U 1.6 6mo
13 M 5 5 Ectopic junctional U S S 1 3 yr
14 M 4mo 1 AVRT U S S S 2 3 mo; small VSD
AV =atrioventricular; AVNR =AV node reentry; AVRT = AVreciprocating tachycardia; EPS =electrophysiologic study; F =female; IV = intravenous;
M = male; P = partial response; PI = patient; S = successful; SN = sinus node; SVT = supraventricular tachycardia; U = unsuccessful; VSD = ventricular
septal defect; - = not tried.
venous nadolol dose, but the tachycardia rate decreased by
25%. This outcome was considered unsuccessful and one of
these patients (Group I, Patient 5) had recurrent clinical
tachycardia when oral nadolol was tried. Thus, in six of six
patients with a successful result, the response to short-term
intravenous administration of nadolol and long-term treat-
ment with oral nadolol was concordant (Fig. 1, upper pane!).
Comparison of response to propranolol and nadolol (Table
1, Fig. 1). Twelve patients received both drugs. Intravenous
propranolol was successful in four of six patients (two
patients with ectopic tachycardia and two with AV recipro-
cating tachycardia) but failed to control tachycardia in two
patients; all six patients had a similar response to oral
nadolol therapy. Only oral propranolol was tried in the
remaining six patients; four had excellent clinical control and
two had recurrent clinical tachycardia. Oral nadolol therapy
was tried in five of these patients, who had similar re-
sponses. One patient (Group I, Patient 4) with AV recipro-
cating tachycardia had recurrent tachycardia despite ade-
quate propranolol therapy and a slower but sustained
inducible tachycardia (25% decrease in tachycardia rate)
with intravenous nadolol; oral nadolol was not tried. Thus,
the response to propranolol seemed to predict the results of
long-term nadolol therapy in all patients except one child in
whom oral nadolol was not tried.
Response to long-term oral nadolol therapy and its dosage.
Of the 26 patients who received long-term oral nadolol
therapy, 23 were free of tachycardia during a follow-up
period of 3 to 36 months; 2 had recurrent tachycardia and 1
patient had recurrent tachycardia at a 25% slower rate. In 15
patients, digoxin, a first-line drug, had been unsuccessful. Of
these 15 patients, 1 patient did not receive oral nadolol
therapy because the response to intravenous nadolol was
only partial (AV reciprocating tachycardia); in 3 other pa-
tients oral nadolol was unsuccessful (intraatrial reentry, AV
reciprocating tachycardia and AV node reentry in 1 patient
each). Of the four patients with recurrent tachycardia, one
patient required ablative surgery, one is receiving ftecainide,
one is receiving amiodarone and one was lost to follow-up.
The follow-up period in patients receiving oral nadolol
ranged from 3 months to 3 years (median 1 year). The
effective dose of nadolol in 23 patients who were free of
tachycardia with this protocol ranged between 0.5 and
2.5 mg/kg per day, with a median effective dose of 1 mg/kg
per day. Three patients received 2 mg/kg per day and one
patient required 2.5 mg/kg per day of oral nadolol; all four
patients tolerated this higher dose well during follow-up.
Nine children remained free of tachycardia while receiving
only 0.5 to 0.7 mg/kg per day ofnadolol, whereas three failed
to respond despite doses of 1.5 to 2 mg/kg per day. Doses
<0.5 mg/kg were not tried.
Safety of intravenous and oral nadolol. There was no
significant change in blood pressure after infusion of nadolol.
No patient developed second or third degree AV block after
intravenous or oral nadolol. All patients had a 10% to 20%
decrease in sinus rate, but none had symptomatic bradycar-
dia with intravenous or oral nadolol. Of 26 patients on
long-term oral nadolol therapy, 2 with inactive reactive
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Table 2. Group II: Summary of 13 Children Receiving Prolonged Treatment With Oral Nadolol
Age at Age at
Pt SVT Onset Unsuccessful Therapy Dose Follow-Up
No. Gender (yr) Type of SVT Drugs (yr) (mg/kg per day) Response (yr)
I M 7.5 Narrow QRS SVT 8 I S 2
2 M 14 Narrow QRS SVT 14 0.5 S 1.5
3 M 14 Narrow QRS SVT 14.5 0.7 S I
4 M 5 Narrow QRS SVT
5 M 9 Narrow QRS SVT
6 M 12.3 Narrow QRS SVT
7 M 9 Narrow QRS SVT
8 M 5 Narrow QRS SVT
9 M 5 Narrow QRS SVT
10 F 4 Narrow QRS SVT
II F 5.5 SN reentry
12 F 7 AVRT
13 M 6.3 Automatic junctional
D
D+V
D
9 0.6 S 1.3
9 0.7 S 0.3
14 0.5 S 1.5
11 0.75 S 1.5
5 1.2 S 3
5 1.1 S 1.5
4.5 0.8 S 2
5.5 1.5 S 2
II 1.1 S 2
8.5 0.75 S 2.5
Side Effects
Sleep and personality
change; change to V
Wheezing; change to
atenolol
Wheezing; change to D
Rare headache
Headache; change to D
Rare headache
D = digoxin; V = verapamil; other abbreviations as in Table I.
PROPRANOLOL I NADOLOL STUDY
Figure 1. Response to nadolol and propranolol in children with
supraventricular tachycardia. Upper panel, Comparison of the re-
sponse to intravenous (IV) and oral nadolol in seven children with
supraventricular tachycardia. Lower panel, Comparison of the re-
sponse to intravenous propranolol. oral propranolol and oral nadolol
in 12 children with supraventricular tachycardia (see text for de-
tails).
airway disease had wheezing episodes requiring a change in
drug therapy. One of these patients whose treatment was
changed from nadolol to atenolol because of wheezing had
persistent wheezing and required an oral bronchodilator.
Three other patients had symptoms necessitating
changes in drug therapy as/allows: 1) a 3-month old boy had
abdominal colic at night or nightmares (nadolol dose
1.5 mg/kg) that lessened after therapy was changed from
nadolol to propranolol; 2) a 14-year old boy had sleep and
personality changes (nadolol dose 0.7 mg/kg) and his treat-
ment was changed to verapamil; 3) a 4-year old girl devel-
NADOLOL STUDY
Discussion
Oral nadolol therapy. Supraventricular tachycardia due
to either AV node reentry or accessory bypass is the most
common type of tachycardia in children. Empiric therapy
with digoxin or propranolol, a first generation beta-
adrenoceptor blocking agent, or both, is effective in 64% of
children with supraventricular tachycardia (12). Like pro-
pranolol, nadolol is a nonselective competitive beta-
adrenoceptor blocking agent. However, nadolol has a much
longer plasma half-life of 14 to 24 h (10,11). Nadolol also
lacks intrinsic sympathomimetic activity and membrane-
stabilizing properties. Once a day nadolol therapy has been
shown to be effective in controlling various types of su-
praventricular tachycardia in adults (3-8).
In our study, 11 of 15 patients who did not respond to
digoxin as the first-line drug had a good response to nadolol,
whereas 12 children received propranolol or nadolol as a
first-line drug with successful results. Thus, 23 of 26 children
were free of tachycardia on long-term once a day nadolol
therapy. Although atenolol, a selective betat-adrenoceptor
blocking agent, has also been reported (13) to be successful
in long-term prophylaxis of supraventricular tachycardia in
children, nadolol has the advantage of having the longest
plasma half-life among all available beta-adrenoceptor block-
oped frequent headaches (nadolol dose 0.8 mg/kg) and her
therapy was changed to oral digoxin. Three other patients
had transient headaches and fatigue during the 1st week of
therapy. Except for the 3-month old boy with abdominal
colic, the children whose treatment drug was changed were
receiving a low dose of oral nadolol «0.8 mg/kg). The four
patients who received 2 to 2.5 mg/kg per day of oral nadolol
had no side effects during follow-up. Adverse effects did not
appear to be dose related.
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ing agents. Furthermore, a high degree of concordance was
observed between the response to intravenous nadolol dur-
ing electrophysiologic study and the response to oral nadolol
therapy in our study (six patients). Thus, a successful result
with intravenous nadolol accurately predicts a clinically
good response with long-term oral therapy in children.
Similar results have been reported by other investigators
(3,4) in adults.
Comparison of propranolol and nadolol response in su-
praventricular tachycardia. As reported by Chang et al. (5),
the response to intravenous propranolol during electrophys-
iologic study correctly predicted the long-term response to
oral nadolol therapy in all six of our patients. Because
intravenous nadolol is not yet commercially available in the
United States, the efficacy of oral nadolol can be predicted
by the response to intravenous propranolol during electro-
physiologic pharmacologic study. In our study, five patients
who were treated first with oral propranolol and subse-
quently with oral nadolol had similar clinical responses in the
control of tachycardia. This study shows that children who
are being successfully treated with propranolol given three
or four times a day can safely be given once a day oral
nadolol therapy.
Gillette et al. (1) reported a 25% failure rate with propran-
olol in the management of supraventricular tachycardia in
children, the same rate as in our series (4 of 12 patients).
Pickoffet al. (14) reported the need for high dose propranolol
in the management of selected patients with supraventricular
tachycardia. One reason for failure ofpropranolol in children
is lack of compliance, which may be attributed to the need
for three or four doses/day. Because propranolol is exten-
sively metabolized by the liver, the dose requirement varies
among children and large doses may be needed in some
children for effective control of tachycardia (14). Nadolol
has several advantages over propranolol. Compliance with
once a day nadolol therapy was excellent in our series,
especially in school-aged children. It is not metabolized in
humans and thus has no first-pass effect when taken orally.
In comparison with 95% protein binding of propranolol,
nadolol is only 25% protein bound. In contrast to all other
beta-adrenoceptor blocking agents, nadolol has the unique
property of renal vasodilation (15-17). In experimental ani-
mals, nadolol causes significantly less direct myocardial
depression (18). Because of the long elimination half-life of
nadolol, the possibility of abrupt withdrawal symptoms with
this agent is less likely than with propranolol (19). For these
reasons, we recommend the use of nadolol over propranolol.
Safety. Beta-adrenoceptor blocking agents are well toler-
ated in adults and children. In general, these agents have a
low incidence of proarrhythmia and a lack of organ toxicity,
which are of concern with class I and class III antiarrhyth-
mic agents. Because of its low lipid solubility, nadolol is
thought to cross the blood-brain barrier less readily than
propranolol, causing less central nervous system side ef-
fects. Despite the low lipid solubility of nadolol, three
children had a transient history of headaches and fatigue;
one patient had a sleep disorder and personality changes and
another possibly had nightmares or abdominal colic. In
patients with bronchospastic disease, a relatively selective
betal-adrenoceptor blocking agent is commonly considered
superior to a nonselective beta-blocking agent like nadolol
(13,20). However, selectivity is restricted to low dosage
(15,20) and the therapeutic dosage of these agents may lie
outside the selective range; furthermore, most tissues pos-
sess a mixed group of beta1- and betaz-adrenergic receptors,
even though they may have predominantly one type of
receptor (20). Therefore, selective and nonselective beta-
adrenoceptor blocking agents must be used cautiously in
children with bronchospastic disease. Overall, nadolol was
well tolerated in our patients. In this study, the four patients
who received a relatively high dose of 2 to 2.5 mg/kg per day
of nadolol had no side effects. In children who had side
effects, the dose of nadolol was 0.5 to 0.7 mg/kg, suggesting
that these side effects were probably not dose related.
Conclusions. Nadolol, a nonselective beta-adrenoceptor
blocking agent, seems to be safe and effective as aonce a day
drug in children with supraventricular tachycardia. The
efficacy of oral nadolol can be predicted by the response to
intravenous propranolol during electrophysiologic pharma-
cologic study. A safe starting oral dose of nadolol is 0.5 to
1 mg/kg per day. The drug is well tolerated with no signifi-
cant short- or long-term adverse effects.
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